LOS ANGELES, CA -- (MARKET WIRE) -- May 08, 2007 -- Molecular Pharmacology (USA) Limited (OTCBB: MLPH) (the “Company”) is pleased to report that two new International Patent Applications in the fields of cytokine mediating compositions and COX-2 inhibition have been added to the company’s technology portfolio, which is held by Cambridge Scientific Pty Ltd, a wholly owned subsidiary of the Company’s largest shareholder, Pharmanet Group Limited, under the terms of the Company’s worldwide exclusive license.
